Navigation Links
Latest RAD001 Study Results Show Further Increase in Time Without Tumor Growth in Patients With Advanced Kidney Cancer
Date:9/15/2008

le's lives by pioneering novel healthcare solutions.

Located in East Hanover, New Jersey, Novartis Pharmaceuticals Corporation is an affiliate of Novartis AG (NYSE: NVS), which provides healthcare solutions that address the evolving needs of patients and societies. Focused solely on growth areas in healthcare, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, cost-saving generic pharmaceuticals, preventive vaccines and diagnostic tools, and consumer health products. Novartis is the only company with leading positions in these areas. In 2007, the Group's continuing operations (excluding divestments in 2007) achieved net sales of USD 38.1 billion and net income of USD 6.5 billion. Approximately USD 6.4 billion was invested in R&D activities throughout the Group. Headquartered in Basel, Switzerland, Novartis Group companies employ approximately 98,000 full-time associates and operate in over 140 countries around the world. For more information, please visit http://www.novartis.com.

Novartis Media Relations

Media only: Investors only:

Geoffrey Cook Jill Pozarek

Novartis Oncology Novartis Corporation

P: +1 862 778 2675 P: +1 212 830 2445

F: +1 973 652 7927

Dana Kahn Cooper

P: +1 732 817 1800

F: +1 732 817 1834


'/>"/>
SOURCE Novartis Pharmaceuticals Corporation
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related medicine technology :

1. Cytels Clinical Innovation Experts Cyrus Mehta and Judith Quinlan Reveal Latest Adaptive Trial Successes at 44th Annual DIA Meeting
2. Latest Cell Publication Describes the Novel Kinase Regulators Using OriGenes Functional Kinome Collection
3. Baxter Presents Latest Clinical Trial Results of GAMMAGARD LIQUID Administered Subcutaneously
4. RAD001 Combined with Sandostatin LAR(R) Depot and as Monotherapy Controls Growth of Rare Pancreatic Neuroendocrine Tumors
5. RAD001 Granted Priority Review in the US Based on Potential to Fill Unmet Medical Need in Patients With Advanced Kidney Cancer
6. Early Data Presented at ASCO Show Potential of RAD001 to Enhance Efficacy of, and Overcome Resistance to, Breast Cancer Treatments
7. RAD001 More Than Doubles Time Without Tumor Growth After Failure of Standard Treatment in Patients With Advanced Kidney Cancer
8. Everolimus (RAD001) Significantly Extends Progression-Free Survival in Advanced Kidney Cancer Patients After Failure of Other Targeted Therapy
9. AstraZeneca and Targacept Announce Top-Line Results from Phase IIb Study of AZD3480 in Alzheimers Disease
10. Most Cancer Treatment Studies Arent Published, Study Finds
11. Enanta Initiates Phase 1 Study on EDP-322, an Oral Antibiotic With Activity Against Hospital- and Community-Acquired MRSA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/16/2009)... Dec. 16 A new ... manage the clinical review of specialty pharmaceuticals has ... of drugs reviewed while reducing costs. ,, AIM, ... company with health plan clients representing over 35 ... Inc. (NYSE: WLP ), adapted the ...
(Date:12/16/2009)... REYKJAVIK, Iceland, December 16 Scientists at,deCODE ... journal Nature the,discovery of a version of a ... genome (SNP) with a major impact on susceptibility ... T2D variant is not only large, but unusual:,if ... variant increases risk of,T2D by more than 30% ...
(Date:12/16/2009)... NEW YORK, December 16 ... the publication of GFT505 (80 mg/day),data ... 50 internationally,recognized expert scientists and clinicians ... the continuing role of generic lipid-modifying,treatments, ... which is commonly observed in patients ...
Breaking Medicine Technology:American Imaging Management's New Specialty Drug Program Delivers Immediate Results 2American Imaging Management's New Specialty Drug Program Delivers Immediate Results 3American Imaging Management's New Specialty Drug Program Delivers Immediate Results 4deCODE Discovers a Major Risk Factor for Type 2 Diabetes Dependent on Parent of Origin 2deCODE Discovers a Major Risk Factor for Type 2 Diabetes Dependent on Parent of Origin 3deCODE Discovers a Major Risk Factor for Type 2 Diabetes Dependent on Parent of Origin 4International, Well-Known Scientific Experts Say That New GFT505 Data Unlikely to Have the Potential to Affect the Established Role of Generic Fenofibrate and Bezafibrate in Managing Atherogenic Dyslipidemia 2International, Well-Known Scientific Experts Say That New GFT505 Data Unlikely to Have the Potential to Affect the Established Role of Generic Fenofibrate and Bezafibrate in Managing Atherogenic Dyslipidemia 3A new bent on fusion 9637 1A new bent on fusion 9637 2Princeton team learns why some drugs pack such a punch 9635 1Princeton team learns why some drugs pack such a punch 9635 2Princeton team learns why some drugs pack such a punch 9635 3ESCO Announces Major Contract Award for Its Thermoforming Business 54966 1ESCO Announces Major Contract Award for Its Thermoforming Business 54966 2
... by the European Commission, ATRIPLA Would Represent the, First and Only Once-Daily ... ... PRINCETON, N.J., FOSTER CITY, Calif. and WHITEHOUSE STATION, N.J., Oct.,18 Bristol-Myers ... and Merck & Co., Inc. (NYSE: MRK ),announced today that the ...
... Society for Reproductive Medicine meeting could significantly improve ability to identify embryos ... patients, AFA supports efforts to bring advanced screening technology to patients as,quickly as ... ... procedures, NEW YORK, Oct. 18 According to results ...
Other Medicine Technology:European CHMP Issues Positive Opinion for ATRIPLA(R) (efavirenz 600 mg/ emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) 2European CHMP Issues Positive Opinion for ATRIPLA(R) (efavirenz 600 mg/ emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) 3European CHMP Issues Positive Opinion for ATRIPLA(R) (efavirenz 600 mg/ emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) 4European CHMP Issues Positive Opinion for ATRIPLA(R) (efavirenz 600 mg/ emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) 5European CHMP Issues Positive Opinion for ATRIPLA(R) (efavirenz 600 mg/ emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) 6European CHMP Issues Positive Opinion for ATRIPLA(R) (efavirenz 600 mg/ emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) 7European CHMP Issues Positive Opinion for ATRIPLA(R) (efavirenz 600 mg/ emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) 8European CHMP Issues Positive Opinion for ATRIPLA(R) (efavirenz 600 mg/ emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) 9European CHMP Issues Positive Opinion for ATRIPLA(R) (efavirenz 600 mg/ emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) 10American Fertility Association Calls for Expanded Research to Advance New Technology to Screen Embryos for Genetic Abnormalities 2American Fertility Association Calls for Expanded Research to Advance New Technology to Screen Embryos for Genetic Abnormalities 3
(Date:12/17/2009)... 17 On the heels of unveiling the ... the 2010 race, LA Marathon officials today announced a ... raising funds for causes ranging from cancer research to ... expanded charity program is in line with the vision ... has the potential to be a huge philanthropic force ...
(Date:12/17/2009)... Dec. 17 /PRNewswire-Asia/ -- China,s leading high-tech,healthcare group, ... Stock Code: 801) is pleased to announce today ... period under review, the Group,s two,associate companies made ... and NASDAQ;,its key businesses have been strengthened, with ... management operations. , Mr. ...
(Date:12/17/2009)... Brandeis University selected Jay and Maureen Neitz, the husband-and-wife ... of gene therapy to treat vision disorders, as the ... Vision Sciences. , The award is funded by a ... from Brandeis graduates Jay Pepose ,75 and Susan K. ... research fellowships in vision science. , The Neitzes, both ...
(Date:12/17/2009)... use in era of sexually explicit messaging, experts say ... and preteens spend hours sending text messages from their ... messages -- sexually explicit material, giving the messaging the ... University of Michigan researchers report. , In fact, a ... are worried about the time their children spend sending ...
(Date:12/17/2009)... firm’s Interim Leadership division as senior vice president. A seasoned executive ... assume her duties at B. E. Smith today. , ... ... Smith recently hired Deirdre Byrne to lead the firm’s Interim ... 20 years of experience in healthcare consulting, Byrne will assume her ...
Breaking Medicine News(10 mins):Health News:LA Marathon Unveils Expanded Charity Program; Sixty Official Charities to Take Part in 2010 Race 2Health News:LA Marathon Unveils Expanded Charity Program; Sixty Official Charities to Take Part in 2010 Race 3Health News:LA Marathon Unveils Expanded Charity Program; Sixty Official Charities to Take Part in 2010 Race 4Health News:Golden Meditech Announces Interim Results of FY2009/10 2Health News:Golden Meditech Announces Interim Results of FY2009/10 3Health News:Vision researchers Jay and Maureen Neitz to receive first Pepose Award from Brandeis 2Health News:'Sexting' by Kids Begets Fretting by Parents 2Health News:Deirdre Byrne Joins B. E. Smith as Senior Vice President, Interim Leadership Services 2Health News:Deirdre Byrne Joins B. E. Smith as Senior Vice President, Interim Leadership Services 3
... According to the latest on breast-feeding, there is no hard and ... Most young mothers would be more than glad to ... feeding, can prove too painful for motherly feelings to override. ... a horrendous time trying to breastfeed when her daughter Deborah was ...
... United States the gays prefer to find out whether their ... than use protection to prevent catching the disease. The ... transmitting the virus, which is on the rise. ... with HIV virus and they continue to have unprotected sex. ...
... the functioning of maternity units in UK is an eye-opener ... affair in the hospitals. In a sting operation conducted by ... some alarming practices. ,Some of the maternity units ... most midwives were overburdened with work. The midwife in charge ...
... United Arab Emirates (UAE) said the government is working to ... country's prevention programme of genetic disorders. ,"We ... child's health. But the choice to have the abortion will ... to be within the religious and social environment," Ali Shakar ...
... National AIDS Control Organisation (NACO) has launched an educational ... is being implemented by all the States and Union ... is aimed at the following learning outcomes: (i) to ... process of growing up during adolescence, HIV/AIDS and drug ...
... Health Minister P.K. Sreemathi and seven others for culpable homicide ... newborns in a hospital due to infection. ... judgement on a complaint by a person regarding infant deaths ... ,The deaths were due to infection the infants contracted in ...
Other Medicine News:Health News:New Research Promises To Take The Pain Off Breast Feeding 2Health News:New Research Promises To Take The Pain Off Breast Feeding 3Health News:Unprotected Sex Among the Gays on the Rise 2Health News:United Kingdom: Maternity Units Exposed! Leaves Much to Be Desired 2Health News:Kerala Health Minister Charged for Infant Deaths in a Hospital 2
... 2000 Digoxin Assay is a ... use in the quantitative analysis ... or plasma. Kits are packaged ... Roche COBAS MIRA, COBAS MIRA ...
The Emit 2000 Digoxin Assay is a homogeneous enzyme immunoassay for use in the quantitative analysis of digoxin in human serum or plasma. Kits are conveniently packaged in Olympus Reagent Cartridges ...
Liquichek Rheumatoid Factor Control is a liquid trilevel control designed to monitor rheumatoid factor testing procedures, including nephelometric and latex agglutination methods....
... The Newmarket Laboratories RPR kits use ... of lipid antigens, which will combine ... or plasma. The particles are suspended ... eliminate non - specific reactions. Positive ...
Medicine Products: